Advertisement
JBIO vs OCS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a StrongBuy and OCS is a StrongBuy.
JBIO's RSI Oscillator recovers from oversold territory
The RSI Oscillator for JBIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 19 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on JBIO as a result. In 77 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for JBIO just turned positive on October 08, 2026. Looking at past instances where JBIO's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where JBIO advanced for three days, in 223 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for JBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
JBIO broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JBIO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.187) is normal, around the industry mean (2.988). P/E Ratio (-14.140) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. JBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
OCS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for OCS moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 19 of the 22 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for OCS just turned positive on October 21, 2026. Looking at past instances where OCS's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCS advanced for three days, in 151 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
OCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for OCS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.992) is normal, around the industry mean (2.988). P/E Ratio (-5.703) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. OCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| JBIO | OCS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 83% | N/A |
| Momentum ODDS (%) | 2 days ago 84% | N/A |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 56% |
| Advances ODDS (%) | 2 days ago 82% | 2 days ago 75% |
| Declines ODDS (%) | 10 days ago 89% | 9 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 54% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JBIO’s FA Score shows that 2 FA rating(s) are green while OCS’s FA Score has 2 green FA rating(s).
- JBIO’s FA Score: 2 green, 3 red.
- OCS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JBIO’s TA Score shows that 4 TA indicator(s) are bullish while OCS’s TA Score has 4 bullish TA indicator(s).
- JBIO’s TA Score: 4 bullish, 5 bearish.
- OCS’s TA Score: 4 bullish, 2 bearish.
Price Growth
JBIO (@Biotechnology) experienced а +12.57% price change this week, while OCS (@Biotechnology) price change was +9.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
JBIO is expected to report earnings on Nov 12, 2026.
OCS is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
JBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, JBIO has been loosely correlated with ARVN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JBIO jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To JBIO | 1D Price Change % | ||
|---|---|---|---|---|
| JBIO | 100% | +1.82% | ||
| ARVN - JBIO | 43% Loosely correlated | -1.37% | ||
| IMNM - JBIO | 43% Loosely correlated | +0.45% | ||
| SYRE - JBIO | 42% Loosely correlated | +1.70% | ||
| EDIT - JBIO | 41% Loosely correlated | -2.71% | ||
| KURA - JBIO | 40% Loosely correlated | -1.00% | ||
More | ||||
OCS and
Correlation & Price change
A.I.dvisor tells us that OCS and PRAX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCS and PRAX's prices will move in lockstep.
| Ticker / NAME | Correlation To OCS | 1D Price Change % | ||
|---|---|---|---|---|
| OCS | 100% | +5.07% | ||
| PRAX - OCS | 33% Poorly correlated | -3.03% | ||
| JSPR - OCS | 32% Poorly correlated | +0.88% | ||
| FTH - OCS | 32% Poorly correlated | -1.06% | ||
| IMNM - OCS | 30% Poorly correlated | +0.45% | ||
| JBIO - OCS | 30% Poorly correlated | +1.82% | ||
More | ||||